Glycomine Closes $68 Million Series B To Advance Into Clinical Trials A Novel Treatment For Pmm2-Cdg, A Rare Glycosylation Disease
Glycomine Closes $68 Million Series B To Advance Into Clinical Trials A Novel Treatment For Pmm2-Cdg, A Rare Glycosylation Disease
06/23/21, 11:04 AM
Location
san carlosMoney raised
$68 million
Round Type
series b
Glycomine, Inc., a biotechnology company focused on developing new therapies for orphan diseases, today announced that it has closed a $68 million Series B financing. The proceeds of the financing will be used to advance Glycomine’s lead drug candidate, GLM101, through initial clinical trials in patients. GLM101 is a novel substrate replacement therapy in development to treat phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG), a rare disease representing a critical unmet medical need.
Company Info
Location
san carlos, california, united states
Additional Info
Glycomine is developing orphan drugs for serious rare disorders of metabolism and protein misfolding for which no other therapeutic options exist. The company's approach is to use replacement therapies – substrates, enzymes, or proteins – and to target those molecules to clinically relevant cellular compartments. The company is based in San Carlos, California and supported by leading international life sciences investors. For more info, visit www.glycomine.com.